Preclinical program targeting mycobacterial infections
- Nontuberculous mycobacteria (NTM)
- M. abscessus complex
- M. avium complex
- Tuberculosis (TB)
- M. tuberculosis
News / Updates
CRS0393 NTM/TB Overview
We are developing a novel class of anti-mycobacterial agents (benzothiazole amides) that target the MmpL3 protein essential for cell wall synthesis. In collaboration with scientists at Colorado State University, the hit-to-lead program has resulted in CRS0393, an advanced compound that shows excellent potency against all mycobacteria tested, including multidrug-resistant strains.
Why It Matters
Chronic respiratory mycobacterial infections with nontuberculous mycobacteria are increasing in incidence and are notoriously difficult to treat. Lung disease manifests as nodular bronchiectasis and/or fibrocavitary disease. Treatment of nontuberculous mycobacterial lung disease is challenging since the potency of available agents is relatively low, resistance to antibacterial agents is common and prolonged treatment with multiple drugs is difficult to tolerate.
Key Areas of Study
- Novel mechanism of action based on inhibition of MmpL3, essential for cell wall synthesis
- Highly potent lead compound
- No pre-existing resistance
- In vivo efficacy in a mouse model of NTM infection
- Oral bioavailability and potential for aerosol/inhaled therapy
- Good activity against M. tuberculosis
Ongoing CRS0393 NTM/TB Studies
Novel anti-mycobacterial candidate CRS0393 is still in pre-clinical development, so no clinical studies are available for this drug candidate at the moment. Please check back soon for further updates.
Become a Part of This Project
Interested in helping further our research into novel antibacterial agents? We’d be thrilled to have your help, either as an investor or a team member.
Have a question or comment? Follow the link below to contact us about general inquiries.
Find work in a team-oriented environment at one of the leading Colorado pharma companies.
If you're interested in becoming an investor to help fund our research and development, contact us today.